has attracted the attention of the attorneys general of California and Florida.
The generic drugmaker Monday disclosed that it had received subpoenas from officials in the two states seeking information relating to the company's price reporting and marketing practices for various drugs.
The Pittsburg-based company made the disclosure in a filing with the
Securities and Exchange Commission
In late July, Mylan agreed to acquire
in a stock-swap deal valued at $4 billion.
Mylan shares closed at $14.98 Monday, near their 52-week, intraday low of $14.24.